In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies challenge Brazilian regulator's right to veto patents

This article was originally published in Scrip

Executive Summary

Companies are finally set to get legal clarity on one of the biggest causes of contention between the pharma industry and Brazilian authorities. The courts will eventually decide on the legality of the medicine regulator's role in vetoing patent applications after Interfarma, the Brazilian pharmaceutical industry association, filed a suit against ANVISA.

You may also be interested in...



Brazil’s New Patent Agreement Is “Real and Concrete Threat” To IP

An agreement between Brazil’s medicines regulator, ANVISA, and the National Institute of Industrial Property, INPI, aimed at clearly defining their respective roles in the patent application process could pose a threat to the patent system, say IPR experts.

EU Pharmaceutical Strategy Roadmap Seen As Weak On Innovation

Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.

Australia’s TGA Seeks Feedback on Data Matrix Code Labeling

The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.

Topics

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel